ADVA
23.4.2020 07:02:05 CEST | Business Wire | Press release
ADVA (ISIN: DE0005103006), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported financial results for Q1 2020 ended on March 31, 2020. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200422005933/en/
Q1 2020 financial summary1
(in thousands of EUR) |
Q1 |
Q1 |
Change |
Q4 |
Change |
|||||
|
2020 |
2019 |
|
2019 |
|
|||||
|
|
|
|
|
|
|||||
Revenues |
132,686 |
128,160 |
3.5% |
151,135 |
-12.2% |
|||||
Pro forma gross profit |
42,275 |
45,132 |
-6,3% |
54,633 |
-22.6% |
|||||
in % of revenues |
31.9% |
35.2% |
-3.3pp |
36.1% |
-4.2pp |
|||||
Pro forma operating income |
-1,671 |
2,748 |
n.a. |
10,333 |
n.a. |
|||||
in % of revenues |
-1,3% |
2.1% |
-3.4pp |
6.8% |
-8.1pp |
|||||
Operating income2 |
-4,038 |
868 |
n.a. |
5,438 |
n.a. |
|||||
Net income2 |
-7,235 |
1,036 |
n.a. |
2,522 |
n.a. |
|||||
|
|
|
|
|
|
|||||
(in thousands of EUR) |
Mar. 31 2020 |
Mar. 31 2019 |
Change |
Dec. 31 2019 |
Change |
|||||
Cash and cash equivalents |
52,753 |
49,323 |
7.0% |
54,263 |
-2.8% |
|||||
Net debt3 |
67,705 |
73,702 |
-8.1% |
61,146 |
10.7% |
1 |
Potential differences due to rounding |
|
2 |
Q1 2020 including EUR 0.8 million and Q4 2019 including EUR 3.2 million one-off expenses |
|
3 |
Q1 2020 including EUR 32.5 million, Q4 2019 including EUR 34.4 million and Q1 2019 including EUR 36.8 million lease liabilities due to IFRS 16 |
Q1 2020 IFRS financial results
Revenues for Q1 2020 decreased by 12.2% to EUR 132.7 million from EUR 151.1 million in Q4 2019 and grew by 3.5% from EUR 128.2 million in the same year-ago period.
Pro forma operating income for Q1 2020 was negative EUR 1.7 million (-1.3% of revenues), substantially down from EUR 10.3 million (6.8% of revenues) in Q4 2019 and also down from EUR 2.7 million (2.1% of revenues) in the same year-ago period. The decline in profitability is mainly due to the lockdown in Wuhan at the beginning of the first quarter and to significant project-related shifts in the product and customer mix in Q1 2020.
Consequently, operating income for Q1 2020 of negative EUR 4.0 million significantly decreased from EUR 5.4 million reported for Q4 2019 and decreased from EUR 0.9 million in the same year-ago quarter. One-off expenses are primarily driven by selective head count reduction and site closures and amounted to EUR 0.8 million in Q1 2020.
ADVA reported a net loss of EUR 7.2 million in Q1 2020 that decreased significantly from a net income of EUR 2.5 million in Q4 2019 and declined from a net income of EUR 1.0 million in Q1 2019.
At quarter-end, the company’s cash and cash equivalents totaled at EUR 52.8 million, representing a decrease of 2.8% compared to EUR 54.3 million at the end of Q4 2019 and an increase of 7.0% compared to EUR 49.3 million in Q1 2019.
The company’s net debt in Q1 2020 increased by EUR 6.6 million to EUR 67.7 million from EUR 61.1 million at the end of Q4 2019 and improved by EUR 6.0 million compared to Q1 2019.
Net working capital at quarter-end was EUR 134.2 million compared to EUR 128.2 million at the end of Q4 2019. Trade account receivables decreased from EUR 96.2 million to EUR 88.2 million and inventories decreased from EUR 105.4 million to 91.5 million, respectively. At the same time trade account payables declined to EUR 45.5 million compared to EUR 73.4 million in the previous quarter.
While demand in Q1 2020 developed positively, there are still increased risks in maintaining the ability to supply. A recession-related decline in demand can also have a negative impact on the business performance of ADVA. Due to the current uncertainties about the further course of the crisis and its effects on ADVA's business, it is not possible to reliably predict further implications for the company. Therefore, the management board has concluded that the guidance of February 20, 2020, outlined in the 2019 annual report cannot be upheld and therefore withdraws the previous outlook for the 2020 financial year. Originally, the company had forecasted increasing revenues to more than EUR 580 million with an increased pro forma operating income of more than 5% of revenues. Additionally, the management board expected an improvement in net debt in the single-digit percentage range and a net promoter score of at least 40%.
Management commentary
“We are currently experiencing a crisis that is unprecedented in the history of the modern, industrialized world. Covid-19 knows no national borders, affects all continents and creates severe challenges for all of us,” said Brian Protiva, CEO, ADVA. “As a network equipment supplier, we serve some of the world’s most critical communications infrastructures. As such, we’re doing everything humanly possible to remain fully operational, while protecting the safety and health of our employees, partners and customers. Order entry from a few large customers was strong in the first quarter, and our main focus is on maintaining our ability to deliver. We have developed a very agile and flexible supply chain, and our development and distribution centers have so far largely avoided the crisis. Apart from a few minor exceptions, our production and supply chains are intact. Clearly, this can worsen suddenly, and that’s why we have developed a strategy that enables us to compensate for production and delivery bottlenecks due to possible location closures.”
“Despite elevated levels of uncertainty on the demand and supply side, we operate in a framework of financial resilience,” commented Uli Dopfer, CFO, ADVA. “We were able to improve our operating cash flow compared to the year-ago quarter while our cash balance of EUR 52.8 million remained on a comfortable level. We have a strong order backlog and are confident that we will grow sequentially in Q2 2020. So far, we haven’t utilized any of the Covid-19-related government loans. However, we are reviewing all meaningful opportunities and actively manage our working capital to ensure balance sheet stability and financial flexibility.”
The company will publish its financial results for Q2 2020 on July 23, 2020.
Conference call details
ADVA will hold a conference call for analysts and investors today, April 23, 2020, to discuss these results and management’s outlook. The company’s CEO, Brian Protiva, and CFO, Uli Dopfer, will host the call at 3:00 p.m. CEST (9:00 a.m. EDT). A question and answer session will follow management presentations.
To participate, please register here . Once registered, you will receive the dial-in details via e-mail.
A corresponding presentation is available on ADVA’s website: https://www.adva.com/en/about-us/investors/financial-results/conference-calls
The complete quarterly statement 3M 2020 (January – March) is available as a PDF here: https://www.adva.com/en/about-us/investors/financial-results/financial-statements
A replay of the call will be available here: https://www.adva.com/en/about-us/investors/financial-results/conference-calls
Forward-looking statements
The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of ADVA. ADVA is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of ADVA or the market in the shares of ADVA.
Use of pro forma financial information
ADVA provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of ADVA’s operating results from one financial period to another. ADVA believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, expenses related to restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200422005933/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease1.5.2026 23:28:00 CEST | Press release
Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib)Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily JakafiJakafi XR will be available for pharmacy orders by May 8 Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meetin
Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 18:08:00 CEST | Press release
Drivers and team members of Formula 1® were reunited with their loved ones during a night that also celebrated the new partnership between Barilla and the Visa Cash App Racing Bulls Formula 1® Team. A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines wer
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 12:07:00 CEST | Press release
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the
Andersen Consulting styrker sine kompetencer inden for digital transformation med Weexa1.5.2026 10:07:00 CEST | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Weexa, en global leverandør af løsninger inden for digital transformation, B2B-integration og digitalisering af forsyningskæden. Med hovedsæde i Frankrig leverer Weexa end-to-end-tjenester, der hjælper organisationer med at optimere, sikre og skalere deres digitale økosystemer. Virksomheden specialiserer sig i styring af B2B-datastrømme og digitalisering, hvilket muliggør problemfri kommunikation mellem applikationer både internt og på tværs af organisationer gennem teknologier som EDI, API'er og e-fakturering. Weexa tilbyder også SAP-integration og supply chain-løsninger til styring af lager og transport, sideløbende med strategisk rådgivning, projektlevering og vedligeholdelse af tredjepartsapplikationer. Weexa betjener organisationer inden for fødevaresektoren, detailhandel, engros, logistik, transport, bilindustrien, sundheds- og mediesektoren og hjælper globale virksomheder med at optimere deres ydeevne samt at overholde de nyeste
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
